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A B S T R A C T
This retrospective study reports the early experience with lacosamide (LCM) as adjunctive therapy in
Spanish patients with refractory focal epilepsy. Sixty patients (mean age 38.3 years, 54% women, mean
epilepsy duration 27.2 years, mean seizure rate 9.7/month, and 28% with mainly nocturnal seizures)
taking 2 antiepileptic drugs (mean 2.2) were included. LCM maintenance doses were 200, 300, 400, and
500 mg/day in 31, 16, 10, and 3 patients, respectively. Patients were followed up for 13–24 months.
Twenty-eight patients (47%) reported a 50% reduction in seizure frequency. A 50% reduction in
seizure frequency was reported by 65% and 40% of patients in the nocturnal seizure and diurnal seizure
subgroups, respectively (p > 0.05). Of the 28 responders, 2 achieved stable periods of seizure freedom of
6 and 11 months after starting LCM. Twenty patients (33%) reported drug-related adverse events (AEs);
the most common was dizziness (16 patients). LCM was withdrawn in 8 patients (13%). There were no
serious AEs. These results support the efﬁcacy and safety of adjunctive LCM in patients with partial-onset
seizures.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is one of the most common chronic neurological
conditions, affecting 0.5–1% of the population worldwide.1 The goal
of antiepileptic therapy is to achieve long-term seizure freedom with
minimal adverse events (AEs). Despite advances in epilepsy
treatment and the development of new antiepileptic drugs (AEDs),
30% of patients continue to experience uncontrolled seizures.2,3
Partial epilepsy represents 60% of the drug-resistant epilepsies.4
Partial seizures can occur during both sleep (nocturnal seizures)
and wakefulness (diurnal seizures); the distribution is variable and
differs according to the type of epilepsy.5,6 Nocturnal seizures
profoundly disrupt sleep structure, which can cause daytime
somnolence and loss of concentration during daily activities.5 Also,
the risk of sudden unexplained death in epilepsy is increased in
patients with nocturnal seizures.7,8 Therefore, effective treatment
of patients with nocturnal seizures is very important. Some studies* Corresponding author at: Epilepsy Unit, Department of Neurology, Hospital
Clı´nico San Carlos, Profesor Martı´n Lagos, S/N, 28040 Madrid, Spain.
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doi:10.1016/j.seizure.2011.08.005have shown that AEDs that block voltage-gated sodium channels
are more effective than other AEDs for the treatment of nocturnal
seizures.9,10 These ﬁndings, as well as evidence that mutations in
the voltage-gated sodium channel genes SCN1A, SCN2A, and
SCN1B are involved in several types of epilepsy, strongly support
the development of additional AEDs acting on voltage-gated
sodium channels.11,12
Lacosamide (LCM) is a new AED approved as adjunctive therapy
for partial-onset seizures. It has a novel dual mechanism of action
consisting of selective enhancement of slow inactivation of voltage-
dependent sodium channels13 and modulation of collapsin-
response mediator protein 2.14 Its approval was based on efﬁcacy
and safety results from three phase III double-blind placebo-
controlled trials,15–17 but little is known about its efﬁcacy in daily
clinical practice,18 especially in patients with nocturnal seizures.
This study retrospectively analyzed postmarketing data from
LCM-treated patients in four Spanish hospitals to characterize the
efﬁcacy and safety proﬁle of LCM, and compare its effect in patients
with nocturnal versus diurnal seizures.
2. Methods
This observational, retrospective, multicenter study included 60
patients treated with LCM as adjunctive therapy for partial-onsetvier Ltd. All rights reserved.
Table 1
Etiology of epilepsy.
Etiology Number of patients (%)
Hippocampal sclerosis 9 (15)
Cortical dysplasia 8 (13)
Meningoencephalitis 5 (8)
Brain tumor 5 (8)
Perinatal infarct 2 (3)
Brain malformation 1 (2)
Cerebral hypoxia 1 (2)
Ischemia 1 (2)
Mitochondrial disease 1 (2)
Down’s syndrome 1 (2)
Unknown 26 (43)
Table 2
Drug-related adverse events reported by patients during lacosamide therapy.




Behavioral alteration and agitation 1 (2)
Pain in ﬁnger and toe-nails 1 (2)
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January 2011 at four epilepsy units in Spain.
All patients received oral LCM tablets as adjunctive therapy for
refractory focal epilepsy. None of the patients included in the study
had participated in premarketing clinical trials of LCM. The
decision to initiate LCM treatment was made according to clinical
criteria. To improve the tolerability of LCM, treatment was titrated
more slowly than recommended by the manufacturer. Treatment
was initiated at 50 mg once daily, followed by weekly increments
of 50 mg/day to a target dose of 200–500 mg/day. Doses were
adjusted individually depending on seizure control and adverse
events (AEs).
All patients gave their written informed consent to the
collection of their clinical data for the study. Data were obtained
at the sites and later stored in a common database for analysis.
Information was recorded on demographics, epilepsy history
(duration, seizure type, and etiology), occurrence of nocturnal and
diurnal seizures, psychiatric comorbidities, previous and concom-
itant AEDs, LCM daily dose, seizure frequency (recorded from
patients’ diaries that were reviewed at each visit to the site), and
drug-related AEs. Drug-related AEs were evaluated from sponta-
neous patient reports and direct questioning at the site.
Epilepsy was classiﬁed according to the International League
Against Epilepsy criteria.19 Diagnosis of epilepsy was established
by seizure description, age of onset, family history of epilepsy,
response to AED therapy, electroencephalography (EEG), and
magnetic resonance imaging ﬁndings.
Two groups were analyzed: the diurnal seizure (DS) group
included patients with >50% of seizures occurring while awake,
and the nocturnal seizure (NS) group included patients with >50%
seizures occurring during night or daytime sleep. Included patients
all slept with someone who was able to recognize seizures to
facilitate accurate recording of the number of seizures a patient
had. The 50% response rate (proportion of patients with a 50%
reduction in seizure frequency) was assessed in the overall patient
population, and in both the DS and NS subgroups.
3. Results
3.1. Patient characteristics
A total of 60 patients (54% women) were included. The mean
age at the time of inclusion was 38.3 years (range 21–69). The
average time since diagnosis of epilepsy was 27.2 years (range 1–
67). All patients had refractory focal epilepsy with monthly
seizures. Patients experienced a mean of 9.7 seizures per month
(range 2–60). Seventeen of 60 patients (28%) had >50% nocturnal
seizures and were included in the NS group; of these 17 patients,
11 had exclusively nocturnal seizures. The etiology of epilepsy was
undetermined in 43% of patients, while hippocampal sclerosis and
cortical dysplasia were the most common causes of epilepsy in
patients with known etiology (Table 1). Based on the symptom-
atology of seizures and MRI ﬁndings in the cases who had
structural alterations on MRI, twenty-two patients (37%) were
diagnosed with temporal lobe epilepsy (9 with hippocampal
sclerosis) and the remaining patients were diagnosed with
extratemporal lobe epilepsy. None of the patients had undergone
surgery and therefore the exact epileptogenic area could not be
conﬁrmed in the absence of video EEG monitoring.
During the study, patients were taking a mean of 2.2 drugs
(range 1–4) and six patients (10%) were taking concomitant
antidepressant treatment. The most common background AEDs
were levetiracetam (LEV) [25 patients], carbamazepine (CBZ) [19
patients], lamotrigine (LTG) [16 patients], topiramate (TPM) [13
patients], and oxcarbazepine (OXC) [13 patients]. Patients had
failed a mean of 6.3 AEDs (range 3–13) before starting treatmentwith LCM. Patients were followed up on LCM treatment for 13–24
months.
3.2. Efﬁcacy
The stable dose of LCM achieved was 200 mg/day in 31 patients
(52%), 300 mg/day in 16 patients (27%), 400 mg/day in 10 patients
(17%), and 500 mg/day in 3 patients (5%).
A 50% reduction in seizure frequency was achieved in 28
patients (47%), of whom 11, 11 and 6, respectively, were receiving
LCM 200 mg/day, 300 mg/day and 400 mg/day. A 50% reduction
in seizure frequency was observed 11/17 patients (65%) in the NS
group and 17/43 patients (40%) in the DS group. The difference
between the groups was not statistically signiﬁcant (p > 0.05). In
addition, 2 of the 28 responder patients achieved stable periods of
seizure freedom of 6 and 11 months after starting LCM.
Background AED treatment consisted of valproate and LEV in
one of the seizure-free patients, and zonisamide (ZNS) in the other;
one seizure-free patient was in the NS group. The percentage of
responders in the subgroup of patients who were taking classic
sodium channel modulators was 45% (18/40) compared with 75%
(15/20) in the subgroup who were not taking this type of AED.
Therefore, these data do not indicate that use of LCM with other
sodium channel modulators is more effective. However, these data
do suggest that the combination of LCM with drugs with a different
action mechanism might be more beneﬁcial. Seven patients (12%)
reported 30–50% reductions in seizure frequency, of whom 3 were
in the NS group, and 17 patients (28%) experienced no change in
seizure frequency.
3.3. Adverse events
Twenty out of 60 patients (33%) reported drug-related AEs
during LCM therapy (Table 2). The most common drug-related AE
was dizziness, which occurred in 16 patients. More than 50% of
patients who reported dizziness (12/16) were taking other sodium
channel modulators, 7 were taking CBZ and 5 were taking OXC.
Doses of CBZ and OXC were reduced, but in 5 cases (42%) LCM had
to be withdrawn due to intolerance. Two patients experienced an
increase in seizure frequency after they were on LCM. Background
AED therapy in these 2 patients consisted of ZNS and OXC in 1
patient, and ZNS and LTG in the other. Both patients improved after
LCM was withdrawn. One patient experienced confusion and
I. Garcı´a-Morales et al. / Seizure 20 (2011) 801–804 803agitation. LCM was withdrawn in 8 patients (13%); the reason for
withdrawal was AEs in 6 patients and increased seizure frequency
in 2 patients. The rate and causes of treatment interruption were
similar to what has been published in the literature. There were no
serious AEs reported during the study.
4. Discussion
The patient population in the current study was similar to that
in three previously published double-blind, placebo-controlled
trials of LCM,15–17 with the exception of a longer history of epilepsy
(27.2 years versus 22.3 and 24.5 years, respectively). The 50%
response rate (47%) was higher than that observed in previous
trials,15–17 which had response rates of 38–41% at 400–600 mg/day
dosages of LCM, and response rates of 33–35% at 200 mg/day. The
response rate was also greater than that observed in a post-
marketing study published by Wehner et al.,18 which reported a
50% reduction in seizure frequency in 32% of patients. In addition,
most patients achieving a 50% reduction in seizure frequency in
the current study were on relatively low doses of LCM: 11/28
patients were receiving 200 mg/day and 11/28 were receiving
300 mg/day. This may be related to the common practice in our
centers to evaluate response to low doses for longer periods of
time, even for one or two months, in patients on polytherapy.
The clinical characteristics of patients who experienced a 50%
reduction in seizure frequency were heterogeneous, and did not
allow the identiﬁcation of a type of patient who had the greatest
beneﬁt from LCM treatment. Since LCM is a sodium channel
blocker and seizures occurring during sleep might have a better
response to carbamazepine and other sodium channel blockers,9,10
we investigated whether there was a greater response rate in the
NS group. Although there was a slightly better response in the NS
group (65% vs. 40%), this difference did not reach statistical
signiﬁcance. None of the patients experienced worsening of
nocturnal seizures.
The effects of AEDs on nocturnal seizures and sleep architecture
have not yet been systematically addressed.20 However, some
studies have found that sodium channel blockers such as LTG and
CBZ tend to control seizures occurring during sleep better than
other AEDs.10,21 Sodium channel blockers are also thought to cause
less disruption of sleep patterns, and thus do not alter the quality of
sleep.22,23 In addition, sodium channel blockers have not been
associated with worsening of nocturnal seizures, as has been
reported in patients receiving benzodiazepines.24 Taking this into
account, it would be interesting to determine if the speciﬁc
mechanism of action of LCM has beneﬁcial effects not only on
nocturnal seizures, but also on sleep quality in patients with
epilepsy.
Although we cannot state that a particularly efﬁcacious
combination of AEDs exists, the two seizure-free patients were
treated with LCM in combination with ZNS or VPA + LEV. These
drugs have a completely different mechanism of action to LCM.
There was no obvious synergy when LCM was given in combina-
tion with other sodium channel modulators.
Regarding the safety of LCM, there were no serious AEs reported
in the study population. As in the three premarketing trials,15–17
the most common AE was dizziness, which occurred in 16 patients,
13 of whom were also receiving other sodium channel modulators
(CBZ and OXC). Doses of CBZ and OXC were reduced and the
dizziness improved in all but four cases who required drug
discontinuation. One patient had an AE not described previously
(confusion and agitation) and it was decided to stop LCM despite
an improvement of seizure frequency. The two patients who had
an increase in seizure frequency suffered focal epilepsy of
unknown etiology and were also being treated with either
ZNS + LTG or OXC. In one of these patients, the seizures tookplace while the patient was in the hospital and could be directly
observed by the physician, who also observed a worsening in the
EEG. In the other patient, the worsening was self-reported by him
and his family. Both patients recovered from clinical seizures and
EEG abnormalities after LCM were withdrawn and were safely
managed as outpatients.Although this study is obviously limited
by its small sample size and its retrospective design, it provides
interesting information which suggests the direction for future
research strategies. Additional studies with a larger sample of
patients are needed to further explore the potential efﬁcacy of
LCM, as well as other AEDs, for controlling nocturnal seizures.
Future studies should focus on which particular subgroups of
patients respond to LCM, and investigate whether there is indeed a
better response in patients with nocturnal seizures.
In conclusion, treatment with adjunctive LCM is effective and
safe in patients with refractory focal epilepsy, and may be an
effective treatment option in patients with seizures that occur
during sleep.
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